Neo Ivy Capital Management Purchases 37,107 Shares of Hims & Hers Health, Inc. $HIMS

Neo Ivy Capital Management raised its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 187.1% during the 2nd quarter, Holdings Channel reports. The fund owned 56,945 shares of the company’s stock after purchasing an additional 37,107 shares during the period. Hims & Hers Health makes up approximately 0.9% of Neo Ivy Capital Management’s investment portfolio, making the stock its 17th biggest position. Neo Ivy Capital Management’s holdings in Hims & Hers Health were worth $2,839,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Quaker Wealth Management LLC bought a new position in Hims & Hers Health during the second quarter valued at $29,000. Bessemer Group Inc. raised its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the first quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Hims & Hers Health during the 1st quarter valued at about $41,000. Finally, Spire Wealth Management bought a new position in shares of Hims & Hers Health during the second quarter valued at approximately $42,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS stock opened at $33.64 on Friday. Hims & Hers Health, Inc. has a 1-year low of $21.36 and a 1-year high of $72.98. The business has a 50-day moving average price of $49.52 and a 200 day moving average price of $51.19. The company has a market capitalization of $7.66 billion, a P/E ratio of 62.30, a PEG ratio of 7.13 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period last year, the business posted $0.32 EPS. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has approved a stock repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages have commented on HIMS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday. KeyCorp assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Reduce” and a consensus price target of $45.27.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $53.48, for a total transaction of $6,852,231.96. Following the completion of the sale, the chief executive officer directly owned 160,425 shares in the company, valued at $8,579,529. This represents a 44.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 145,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the sale, the chief financial officer owned 128,984 shares in the company, valued at $7,139,264.40. This represents a 52.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 630,583 shares of company stock valued at $33,544,943 over the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.